Clinical Trials
AbbVie Provides Update on Phase 3 Study of Ibrutinib in Blood Cancer Diffuse Large B-Cell Lymphoma and Ongoing Ibrutinib Clinical Program
AbbVie , a research-based global biopharmaceutical company, announced an update on a Phase 3 study (DBL3001) of ibrutinib (IMBRUVICA®) in untreated diffuse large B-cell lymphoma...
Clinical Trials
Codexis Doses First Subjects in Phase 1a Trial of CDX-6114
Codexis, Inc , a leading protein engineering company, announces that it has dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114,...
Clinical Trials
Aminex Therapeutics Initiates First Clinical Trial of Novel Immunotherapy AMXT 1501 + DFMO in Cancer Patients
Aminex Therapeutics, Inc., a clinical-stage drug development company focused on advancing a novel cancer immunotherapy, announced it received clearance from the FDA to initiate the...
Clinical Trials
MEI Pharma Presents Phase 1b Clinical Data for ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 ASCO Annual Meeting
MEI Pharma, Inc a pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer. ...
Clinical Trials
AstraZeneca provides update on GALATHEA Phase III trial for Fasenra in chronic obstructive pulmonary disease
AstraZeneca and MedImmune, its global biologics research and development arm, announced top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients with...
Clinical Trials
Medigene AG: Medigene’s Academic Partners Provide Update on Planned MAGE-A1-specific TCR Clinical IIT during CIMT
Planegg (pta/08.05.2018/07:30) Medigene AG (MDG1, Frankfurt, Prime Standard), announced that researchers from Max-Delbrück-Center for Molecular Medicine (MDC) and Charité, both in Berlin, Germany, will present...
Clinical Trials
Nordic Nanovector Presents Preclinical Data at AACR 2018
Nordic Nanovector ASA announces that a poster reporting the anti-tumour effect of Humalutin® (177Lu-conjugated humanized anti-CD37 antibody, 177Lu-NNV003) in preclinical models of non-Hodgkin's lymphoma (NHL)...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.